PUBLISHER: The Business Research Company | PRODUCT CODE: 1350916
PUBLISHER: The Business Research Company | PRODUCT CODE: 1350916
“Lung Cancer Diagnostic And Screening Global Market Report 2023 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on lung cancer diagnostic and screening market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for lung cancer diagnostic and screening? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The lung cancer diagnostic and screening market global report ” from The Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Major players in the lung cancer diagnostic and screening market are: Pfizer Inc., F. Hoffmann-La Roche AG, Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., AstraZeneca Plc, Abbott Laboratories Inc., Medtronic Plc., Danaher Corporation, Siemens Healthcare GmbH, FUJIFILM Corporation, Koninklijke Philips N.V., GE Healthcare Bio Sciences AB, Quest Diagnostics Incorporated, Agilent Technologies Inc., Illumina Inc., Qiagen Inc., Myriad Genetic Laboratories Inc., NeoGenomics Laboratories Inc., Canon Medical Systems Corporation, Eon Health Inc., OncimmuneHoldings Plc, Broncus Medical Inc., OncoCyte, Riverain Technologies LLC, VisionGate, Foundation Medicine Inc., Biodesix, and iDNA.
The global lung cancer diagnostic and screening market is expected to grow from $1.91 billion in 2022 to $2.11 billion in 2023 at a compound annual growth rate (CAGR) of 10.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The lung cancer diagnostic and screening market is expected to reach $3.02 billion in 2027 at a CAGR of 9.4%.
The lung cancer diagnosis and screening market consists of revenues earned by entities by providing positron emission tomography (PET) scanners, and bronchoscopy. The market value includes the value of related goods sold by the service provider or included within the service offering. The lung cancer diagnosis and screening market also includes sales of products such as liquid biopsy kits, molecular testing kits, and biopsy tools. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
Lung cancer diagnosis and screening refers to using examinations and techniques to discover and identify lung cancer in people with the goal of early detection and precise diagnosis for efficient treatment planning. It is commonly used to treat squamous cell carcinomas, adenocarcinoma, and large cell carcinoma.
North America was the largest region in the lung cancer diagnostic and screening market in 2022. The regions covered in lung cancer diagnosis and screening report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The main products of lung cancer diagnostics and screening are instruments, consumables, and accessories. An instrument refers to products that are used to read or analyze the results of a diagnostic product, and process samples for a diagnostic product. The various tests include biomarkers tests, imaging tests, biopsy, blood tests, and others used for various cancer types such as non-small cell lung cancer, and small cell lung cancer. These are used by various end-users such as hospitals, independent diagnostic laboratories, diagnostic imaging centers, cancer research institutes, and others.
The increasing prevalence of lung cancer is expected to propel the growth of the lung cancer diagnostic and screening market going forward. Lung cancer is a malignant disease with symptoms such as coughing, chest pain, and difficulty breathing that is defined by the unchecked proliferation of abnormal cells in the lung tissues. Lung cancer diagnosis and screening help lung cancer patients early diagnose the disease with various tests, including an incisional biopsy and a bronchoscopy. For instance, in January 2023, according to the American Cancer Society, a US-based government organization, in the United States, there were approximately 238,340 new cases of lung cancer (117,550 in men and 120,790 in women). Further, there were reportedly 127,070 deaths from lung cancer (67,160 in men and 59,910 in women). Therefore, the rise in the prevalence of lung cancer is driving the growth of the lung cancer diagnostic and screening market.
Technological innovations are a key trend gaining popularity in the lung cancer diagnostics and screening market. Major companies operating in the lung cancer diagnostics and screening market are introducing innovative technologies to sustain their position in the market. For instance, in December 2021, Auris Health, a US-based robotic medical company, introduced the MONARCH Robotic-Assisted Bronchoscopy procedure, the first MONARCH procedure. This procedure allows physicians to accurately diagnose small and hard-to-reach lung nodules, which enables biopsy for early diagnosis and treatment of lung disease.
In January 2022, RadNet Inc., a US-based radiology company, acquired Aidence BV for an undisclosed amount. The acquisition is expected to enhance RadNet Inc.'s leadership in developing and deploying AI to improve patient care and health and accelerate growth and innovation pipeline to provide automated and integrated AI oncology solutions for clinicians. Aidence BV is a Netherlands-based healthcare technology company focusing on clinical solutions for lung cancer screening and pulmonary nodule treatment.
The countries covered in the lung cancer diagnosis and screening market report are: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
The lung cancer diagnostics and screening market research report are one of a series of new reports from The Business Research Company that provides lung cancer diagnostics and screening market statistics, including lung cancer diagnostics and screening industry global market size, regional shares, competitors with a lung cancer diagnostics and screening market share, detailed lung cancer diagnostics and screening market segments, market trends and opportunities, and any further data you may need to thrive in the lung cancer diagnostics and screening industry. This lung cancer diagnostics and screening market research report deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.